Please note that you can not receive CE credits for watching past webinars.
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA). Seglentis contains tramadol, a short-acting opioid, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for adults in the management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
When adjusters have to jump through hoops to make referrals, they lose precious time. When it comes to specialty services, we have your back.
In this upcoming webinar, hear the latest from Enlyte experts on Michigan’s no-fault fee schedule, including product info and regulatory changes.
Under its new parent brand, Mitchell, Genex and Coventry launch first edition of Enlytened, examining continuing impact of COVID-19 on innovation and technology
SAN DIEGO, CA—October 13, 2021—Mitchell, Genex and Coventry formally announced today the creation of their new parent brand, Enlyt
As a unified brand, Enlyte aligns the companies’ teams to enable improved client focus, while leveraging the breadth of solutions and expertise from all three businesses.